Format

Send to

Choose Destination
Expert Opin Drug Metab Toxicol. 2005 Dec;1(4):595-611.

Breast cancer resistance protein in pharmacokinetics and drug-drug interactions.

Author information

1
Millennium Pharmaceutics, Inc., DMPK, 45 Sidney St., Cambridge, MA 02139, USA. cindy.xia@mpi.com

Abstract

Breast cancer resistance protein (BCRP), also known as ABCG2, ABCP and MXR, is a member of the ATP-binding cassette transporter G family. BCRP functions as a biological barrier that extrudes xenobiotics out of cells. The broad substrate specificity and tissue distributions of BCRP in the body make this transporter one of the major efflux transporters in chemotherapy. Recent studies have demonstrated that BCRP exerts a great impact on drug absorption and disposition. This review focuses on the role of BCRP in pharmacokinetics as well as in vitro and in vivo strategies to evaluate hepatic/intestinal BCRP-mediated drug transports and drug-drug interactions. The impacts of polymorphism and gender difference of BCRP are also discussed.

PMID:
16863427
DOI:
10.1517/17425255.1.4.595
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center